These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 8157978)

  • 1. Serum IgA-mediated neutralization of HIV type 1.
    Burnett PR; VanCott TC; Polonis VR; Redfield RR; Birx DL
    J Immunol; 1994 May; 152(9):4642-8. PubMed ID: 8157978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides.
    Vogel T; Kurth R; Norley S
    J Immunol; 1994 Aug; 153(4):1895-904. PubMed ID: 7519220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralization of human immunodeficiency virus type 1 (HIV-1) mediated by parotid IgA of HIV-1-infected patients.
    Moja P; Tranchat C; Tchou I; Pozzetto B; Lucht F; Desgranges C; Genin C
    J Infect Dis; 2000 May; 181(5):1607-13. PubMed ID: 10823760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteers.
    Rubinstein A; Goldstein H; Pettoello-Mantovani M; Mizrachi Y; Bloom BR; Furer E; Althaus B; Que JU; Hasler T; Cryz SJ
    AIDS; 1995 Mar; 9(3):243-51. PubMed ID: 7755912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contrasting IgA and IgG neutralization capacities and responses to HIV type 1 gp120 V3 loop in HIV-infected individuals.
    Kozlowski PA; Chen D; Eldridge JH; Jackson S
    AIDS Res Hum Retroviruses; 1994 Jul; 10(7):813-22. PubMed ID: 7986587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons.
    Mazzoli S; Lopalco L; Salvi A; Trabattoni D; Lo Caputo S; Semplici F; Biasin M; Bl C; Cosma A; Pastori C; Meacci F; Mazzotta F; Villa ML; Siccardi AG; Clerici M
    J Infect Dis; 1999 Sep; 180(3):871-5. PubMed ID: 10438383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High prevalence of serum IgA HIV-1 infection-enhancing antibodies in HIV-infected persons. Masking by IgG.
    Kozlowski PA; Black KP; Shen L; Jackson S
    J Immunol; 1995 Jun; 154(11):6163-73. PubMed ID: 7751656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection.
    Turbica I; Simon F; Besnier JM; LeJeune B; Choutet P; Goudeau A; Barin F
    J Med Virol; 1997 Jul; 52(3):309-15. PubMed ID: 9210041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV neutralizing IgA in exposed seronegative subjects recognise an epitope within the gp41 coiled-coil pocket.
    Pastori C; Barassi C; Piconi S; Longhi R; Villa ML; Siccardi AG; Clerici M; Lopalco L
    J Biol Regul Homeost Agents; 2000; 14(1):15-21. PubMed ID: 10763886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.
    Braibant M; Brunet S; Costagliola D; Rouzioux C; Agut H; Katinger H; Autran B; Barin F
    AIDS; 2006 Oct; 20(15):1923-30. PubMed ID: 16988513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent and early HIV-1MN neutralizing capacity in sera from Dutch HIV-1 seroconverters is related to antibody reactivity to peptides from the gp120 V3 domain.
    Zwart G; Back NK; Ramautarsing C; Valk M; van der Hoek L; Goudsmit J
    AIDS Res Hum Retroviruses; 1994 Mar; 10(3):245-51. PubMed ID: 8018385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
    Staats HF; Nichols WG; Palker TJ
    J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative studies on neutralisation of primary HIV-1 isolates by human sera and rabbit anti-V3 peptide sera.
    Lawoko AL; Johansson B; Hjalmarsson S; Christensson B; Ljungberg B; Al-Khalili L; Sjölund M; Pipkorn R; Fenyö EM; Blomberg J
    J Med Virol; 1999 Oct; 59(2):169-79. PubMed ID: 10459152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing as well as non-neutralizing polyclonal immunoglobulin (Ig)G from infected patients capture HIV-1 via antibodies directed against the principal immunodominant domain of gp41.
    Burrer R; Haessig-Einius S; Aubertin AM; Moog C
    Virology; 2005 Mar; 333(1):102-13. PubMed ID: 15708596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgA immunity in HIV type 1-infected chimpanzees. I. Systemic immunity.
    Black KP; Fultz PN; Girard M; Jackson S
    AIDS Res Hum Retroviruses; 1997 Oct; 13(15):1263-72. PubMed ID: 9339843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralization of HIV-1 subtypes: implications for vaccine formulations.
    Smith TL; van Rensburg EJ; Engelbrecht S
    J Med Virol; 1998 Nov; 56(3):264-8. PubMed ID: 9783696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
    Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
    Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.